title: Proposed mechanisms of action for prostate cancer vaccines.
abstract: Prostate cancer is responsible for the deaths of more than 33,000 American men every year. Once this disease has become metastatic, there is no curative treatment. Alternative therapies to chemotherapy and radical prostatectomy are being increasingly explored. Prostate cancer vaccines--which trigger a tumour-specific cytotoxic-T-lymphocyte-mediated immune attack by the patient's immune system--have been investigated in clinical trials with modest, yet encouraging, results. When developing and administering prostate cancer vaccines, it is critical to consider how vital parameters, such as the stage of disease progression and the nature of adjuvant therapies, could influence treatment outcome. Of particular interest are current and future strategies for diminishing the activity of regulatory T lymphocytes.
authors: Division of Pharmaceutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA.
authors: Sean M
authors: SM
authors: Geary
authors: Caitlin D
authors: CD
authors: Lemke
authors: David M
authors: DM
authors: Lubaroff
authors: Aliasger K
authors: AK
authors: Salem
mesh_terms: D019496:Cancer Vaccines / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology; D014020:Tissue Extracts / Q000627:therapeutic use
chemical_list: D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T
references: J Biol Chem. 1978 Dec 25;253(24):8721-7
references: 214430
references: J Clin Oncol. 2005 Sep 1;23(25):6043-53
references: 16087944
references: Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14987-92
references: 18818309
references: Annu Rev Cell Dev Biol. 2006;22:409-37
references: 16822173
references: Cancer. 2009 Aug 15;115(16):3670-9
references: 19536890
references: J Clin Oncol. 2006 Jul 1;24(19):3089-94
references: 16809734
references: Urology. 1981 Mar;17(Suppl 3):40-53
references: 7010755
references: Nat Med. 2007 Oct;13(10):1155-9
references: 17917664
references: Cell Immunol. 2007 Apr;246(2):92-102
references: 17678637
references: Hum Gene Ther. 1996 Mar 1;7(4):515-23
references: 8800746
references: Clin Breast Cancer. 2006 Jun;7(2):176-9
references: 16800982
references: Nat Rev Microbiol. 2008 Jul;6(7):529-40
references: 18552863
references: N Engl J Med. 2010 Aug 19;363(8):711-23
references: 20525992
references: Ann N Y Acad Sci. 2010 Oct;1209:99-108
references: 20958322
references: J Exp Med. 1999 Aug 2;190(3):355-66
references: 10430624
references: J Virol. 2008 Nov;82(21):10735-46
references: 18715932
references: Expert Rev Vaccines. 2012 Jul;11(7):857-68
references: 22913261
references: J Clin Oncol. 2004 Jun 1;22(11):2122-32
references: 15169798
references: J Immunol. 2001 Jan 15;166(2):731-5
references: 11145643
references: Int J Cancer. 2001 Dec 15;94(6):842-9
references: 11745487
references: J Clin Oncol. 2009 Sep 1;27(25):4035-7
references: 19635998
references: J Immunol. 2010 Dec 15;185(12):7480-6
references: 21076062
references: Eur Urol. 2012 Apr;61(4):639-47
references: 22036643
references: Immunol Rev. 1997 Oct;159:137-54
references: 9416508
references: Arch Dermatol Res. 1998 Oct;290(10):547-52
references: 9836505
references: Cancer Immunol Immunother. 2011 Sep;60(9):1309-17
references: 21626029
references: Clin Cancer Res. 2011 Jun 15;17(12):3984-92
references: 21543518
references: Clin Cancer Res. 2008 Jun 1;14(11):3536-44
references: 18519787
references: Eur Urol. 2008 Apr;53(4):694-708
references: 18061335
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Mol Ther. 2009 Oct;17(10):1677-82
references: 19672244
references: PLoS Pathog. 2007 Feb;3(2):e25
references: 17319743
references: PLoS One. 2012;7(5):e36823
references: 22606294
references: Clin Cancer Res. 2007 Jul 1;13(13):3883-91
references: 17606721
references: Immunol Rev. 2007 Dec;220:47-59
references: 17979839
references: J Clin Oncol. 2009 Sep 1;27(25):4047-54
references: 19636017
references: Vaccine. 2006 Aug 28;24(35-36):6155-62
references: 16876291
references: PLoS One. 2011 Apr 20;6(4):e18801
references: 21533099
references: Nat Rev Immunol. 2005 Apr;5(4):296-306
references: 15803149
references: Prostate. 2004 Aug 1;60(3):197-204
references: 15176049
references: Lancet Oncol. 2012 May;13(5):501-8
references: 22326924
references: J Clin Oncol. 2010 Mar 1;28(7):1099-105
references: 20100959
references: Expert Rev Vaccines. 2007 Apr;6(2):255-66
references: 17408374
references: Science. 2008 Apr 25;320(5875):531-5
references: 18436786
references: Cancer Immunol Immunother. 2010 May;59(5):663-74
references: 19890632
references: Cancer Res. 1993 Nov 1;53(21):5274-83
references: 8221662
references: Nature. 2000 Aug 17;406(6797):782-7
references: 10963608
references: J Clin Immunol. 2012 Feb;32(1):25-35
references: 22048979
references: Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):14994-5
references: 15479762
references: Mol Ther. 2006 Feb;13(2):320-7
references: 16185933
references: Curr Opin Immunol. 2001 Feb;13(1):114-9
references: 11154927
references: J Immunol. 2007 Feb 1;178(3):1512-22
references: 17237400
references: Methods. 2003 Nov;31(3):232-42
references: 14511956
references: Int J Cancer. 2007 Oct 1;121(7):1520-8
references: 17565748
references: Clin Cancer Res. 2009 Dec 1;15(23):7375-80
references: 19920098
references: Prostate. 2005 Feb 15;62(3):217-23
references: 15389792
references: Cancer Cell. 2005 Mar;7(3):239-49
references: 15766662
references: Cancer Res. 1999 Nov 15;59(22):5800-7
references: 10582702
references: Cancer Res. 2002 Sep 15;62(18):5260-6
references: 12234994
references: Cancer Res. 2010 Apr 15;70(8):3052-61
references: 20388795
references: J Interferon Cytokine Res. 2000 Dec;20(12):1071-6
references: 11152573
references: JAMA. 1999 May 5;281(17):1591-7
references: 10235151
references: Blood. 2010 Jun 3;115(22):4322-4
references: 20522716
references: Cancer Immunol Immunother. 2010 May;59(5):769-77
references: 19940990
references: Cancer. 2008 Sep 1;113(5):975-84
references: 18646045
references: Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1520-9
references: 15050332
references: Onco Targets Ther. 2011;4:33-41
references: 21691576
references: Virology. 2007 Mar 15;359(2):349-61
references: 17056088
references: Nat Rev Urol. 2012 May 29;9(7):376-85
references: 22641164
references: Br J Cancer. 2004 Aug 16;91(4):688-94
references: 15280930
references: J Exp Med. 2005 Dec 19;202(12):1691-701
references: 16365148
references: N Engl J Med. 2011 Jun 30;364(26):2517-26
references: 21639810
references: J Natl Cancer Inst. 2012 Feb 22;104(4):273-9
references: 22232132
references: J Cell Biochem. 2011 Aug;112(8):1969-77
references: 21465529
references: Mol Ther. 2006 Apr;13(4):716-28
references: 16480930
references: Curr Oncol. 2011 Jun;18(3):e150-7
references: 21655153
references: N Engl J Med. 2010 Jul 29;363(5):411-22
references: 20818862
references: Annu Rev Immunol. 2003;21:377-423
references: 12543935
references: Ann Intern Med. 2003 Apr 1;138(7):550-9
references: 12667025
references: Lancet Oncol. 2012 May;13(5):509-17
references: 22326922
references: Cell. 2001 Aug 10;106(3):255-8
references: 11509172
references: J Virol. 2006 Mar;80(5):2225-33
references: 16474130
references: Cancer J. 2010 Jul-Aug;16(4):304-10
references: 20693840
references: J Immunother. 2010 Jul-Aug;33(6):639-47
references: 20551832
references: Eur Urol. 2011 Aug;60(2):279-90
references: 21592649
references: J Immunol. 1999 Dec 15;163(12):6762-8
references: 10586075
references: Cell Death Differ. 2007 Oct;14(10):1848-50
references: 17657249
references: Hum Gene Ther. 2006 Feb;17(2):220-9
references: 16454655
references: J Clin Oncol. 2010 Jul 1;28(19):3167-75
references: 20516446